BACKGROUND: @entity463 ( @entity463 ) is the most common @entity1221 in adults. Standard-of-care therapy includes surgical resection, radiotherapy and @entity2903 , but nearly all @entity1 experience disease progression. The purpose of this study was to describe 2 cohorts of @entity1 with recurrent @entity463 submitted to second-line treatment with @entity4174 / @entity11770 / @entity1891 ( @entity1485 ) or bevacizumab/ @entity2600 (BI). MATERIAL AND METHODS: Retrospective analysis of @entity463 @entity1 treated in our center with @entity1485 or BI, after progression with @entity2903 , between 2004 and 2012. RESULTS: Among 60 @entity1 , 41 were treated with BI and 19 with @entity1485 . According to the Macdonald criteria, the overall response rate in the BI group was 66% (n = 27) while it was 11% (n = 2) in the @entity1485 group. The median progression-free survival was 5 and 3 months in the BI and @entity1485 group, respectively. The median @entity1349 ( @entity1349 ) since second-line chemotherapy was 9 months in the BI group and 5 months in the @entity1485 group. The latter group had a worse @entity137 profile (grade 3-4: 52.6% vs. 22.0%; grade 1-2: 89.5% vs. 68.3%). CONCLUSIONS: The BI cohort had higher response rates, almost twice the @entity1349 and a lower degree of @entity137 in contrast to the @entity1485 group. The small number of @entity1 and historical cohorts limits these comparisons.

Second-Line Chemotherapy in Recurrent XXXX : A 2-Cohort Study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4174 :: ('MESH:D011344', 'Chemical') :: ['procarbazine'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1221 :: ('MESH:D016543', 'Disease') :: ['malignant primary central nervous system tumor'] @entity11770 :: ('MESH:D008130', 'Chemical') :: ['lomustine'] @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine'] @entity1485 :: ('158372', 'Species') :: ['PCV'] @entity2903 :: ('MESH:C047246', 'Chemical') :: ['temozolomide'] @entity463 :: ('MESH:D005909', 'Disease') :: ['GB', 'Glioblastoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity463 :: (MESH:D005909,Disease) :: ['Glioblastoma']
